Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 1717-1721

  Bander, Neil H ^a,c   Trabulsi, Edouard J ^a   Kostakoglu, Lale ^b   Yao, Daniel ^a   Vallabhajosula, Shankar ^b   Smith jones, Peter ^b   Joyce, Maureen A ^a   Milowsky, Matthew ^b   Nanus, David M ^a,b   Goldsmith, Stanley J ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antibodies, monoclonal; Neoplasm metastasis; Prostatic neoplasms; Radioimmunodetection

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY J591 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; MONOCLONAL ANTIBODY J591 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; MONOCLONAL ANTIBODY J591 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOSE CALCULATION; DOSIMETRY; DRUG DISTRIBUTION; DRUG INFUSION; DRUG MECHANISM; DRUG TARGETING; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA; SIDE EFFECT; SOFT TISSUE METASTASIS;

EID: 0141919750     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000091655.77601.0c     Document Type: Article

References (20)

1. Pound, C. R.: Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol, 3: 72, 2001
2. Stanford, J. L., Stephenson, R. A., Coyle, L. M., Cerhan, J., Correa, R., Eley, J. W. et al: Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute. Bethesda, MD: National Institute of Health Publication, No. 99-4543, 1999
3. Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V. et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol, 17: 2506, 1999
4. Oh, W. K. and Kantoff, P. W.: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol, 160: 1220, 1998
5. Horoszewicz, J. S., Kawinski, E. and Murphy, G. P.: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res, 7: 927, 1987
6. Israeli, R. S., Powell, C. T., Fair, W. R. and Heston, W. D.: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res, 53: 227, 1993
7. Israeli, R. S., Powell, C. T., Corr, J. G., Fair, W. R. and Heston, W. D.: Expression of the prostate-specific membrane antigen. Cancer Res, 54: 1807, 1994
8. Wright, G. L., Jr., Haley, C., Beckett, M. L. and Schellhammer, P. F.: Expression of prostate-specific membrane antigen (PSMA) in normal, benign and malignant prostate tissues. Urol Oncol, 1: 18, 1995
9. Troyer, J. K., Beckett, M. L. and Wright, G. L., Jr.: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer, 62: 552, 1995
10. Sokoloff, R. L., Norton, K. C., Gasior, C. L., Marker, K. M. and Grauer, L. S.: A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate, 43: 150, 2000
11. Bostwick, D. G., Pacelli, A., Blute, M., Roche, P. and Murphy, G. P.: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer, 82: 2256, 1998
12. Wright, G. L., Jr., Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D. et al: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48: 326, 1996
13. Sweat, S. D., Pacelli, A., Murphy, G. P. and Bostwick, D. G.: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology, 52: 637, 1998
14. Wynant, G. E., Murphy, G. P., Horoszewicz, J. S., Neal, C. E., Collier, B. D., Mitchell, E. et al: Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate, 18: 229, 1991
15. Deb, N., Goris, M., Trisler, K., Fowler, S., Saal, J., Ning, S. et al: Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res, 2: 1289, 1996
16. Troyer, J. K., Feng, Q., Beckett, M. L. and Wright, G. L.: Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol, 1: 29, 1995
17. Troyer, J. K., Beckett, M. L. and Wright, G. L., Jr.: Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate, 30: 232, 1997
18. Smith-Jones, P. M., Vallabhajosula, S., Navarro, V., Bastidas, D., Goldsmith, S. J. and Bander, N. H.: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med, 44: 610, 2003
19. Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V. et al: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res, 57: 3629, 1997
20. Hamilton, A., King, S., Liu, H., Moy, P., Bander, N. and Carr, F.: A novel humanized antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc Am Assoc Cancer Res, 39: 440, 1998